Cargando…

A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas.

Detalles Bibliográficos
Autores principales:	Bullard, D. E., Thomas, D. G., Darling, J. L., Wikstrand, C. J., Diengdoh, J. V., Barnard, R. O., Bodmer, J. G., Bigner, D. D.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1985
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977022/ https://www.ncbi.nlm.nih.gov/pubmed/3966985

Ejemplares similares

The chemotherapeutic response of a murine (VM) model of human glioma.
por: Bradford, R., et al.
Publicado: (1990)

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
por: Reardon, D A, et al.
Publicado: (2009)

The Ketogenic Diet Is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma
por: Abdelwahab, Mohammed G., et al.
Publicado: (2012)

Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas
por: Flores, Catherine, et al.
Publicado: (2015)

Immunotherapy for malignant glioma
por: Suryadevara, Carter M., et al.
Publicado: (2015)

Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma.
por: Thomas, D. G., et al.
Publicado: (1985)

Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas
por: Wagner, S, et al.
Publicado: (2006)

Theranostic Nanomedicine for Malignant Gliomas
por: d'Angelo, Michele, et al.
Publicado: (2019)

Selective necrosis of malignant gliomas in mice using photodynamic therapy.
por: Sandeman, D. R., et al.
Publicado: (1987)

Glioma Surgical Aspirate: A Viable Source of Tumor Tissue for Experimental Research
por: Day, Bryan W., et al.
Publicado: (2013)

Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas
por: Toda, Masahiro
Publicado: (2013)

Corrigendum: Theranostic Nanomedicine for Malignant Gliomas
por: d'Angelo, Michele, et al.
Publicado: (2020)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Immunotherapies for Malignant Glioma
por: Boussiotis, Vassiliki A., et al.
Publicado: (2017)

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations
por: Sa, Jason K., et al.
Publicado: (2019)

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
por: Grana, C, et al.
Publicado: (2002)

Advances in computational and translational approaches for malignant glioma
por: Bhargav, Adip G., et al.
Publicado: (2023)

The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation
por: Do Nguyen, Hung Thanh, et al.
Publicado: (2016)

The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells
por: Kim, M, et al.
Publicado: (2003)

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
por: Rutkowski, S, et al.
Publicado: (2004)

Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
por: Suryawanshi, Yogesh R., et al.
Publicado: (2021)

The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in vitro and in vivo studies.
por: Bradley, N. J., et al.
Publicado: (1983)

Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas
por: Deguchi, Shoichi, et al.
Publicado: (2020)

HGG-32. UNCOVERING THERAPEUTIC VULNERABILITIES IN MISMATCH REPAIR-DEFICIENT GLIOMAS
por: Boynton, Adam, et al.
Publicado: (2020)

NFB-20. Pre-clinical models of Mismatch Repair Deficient Gliomas
por: Putnam, Ethan, et al.
Publicado: (2022)

HGG-51. Uncovering therapeutic vulnerabilities in mismatch repair-deficient gliomas
por: Boynton, Adam, et al.
Publicado: (2022)

The prognostic influence of bcl-2 in malignant glioma
por: McDonald, F E, et al.
Publicado: (2002)

Tumor Metabolism of Malignant Gliomas
por: Ru, Peng, et al.
Publicado: (2013)

Gene therapy for malignant glioma
por: Okura, Hidehiro, et al.
Publicado: (2014)

Modeling phenotypes of malignant gliomas
por: Sampetrean, Oltea, et al.
Publicado: (2017)

A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity
por: Wiebe, Chris, et al.
Publicado: (2018)

Tumor Treating Fields in the Management of Patients with Malignant Gliomas
por: Ghiaseddin, Ashley P., et al.
Publicado: (2020)

Plasma β‐synuclein, GFAP, and neurofilaments in patients with malignant gliomas undergoing surgical and adjuvant therapy
por: Abu‐Rumeileh, Samir, et al.
Publicado: (2023)

Treatment Resistance Mechanisms of Malignant Glioma Tumor Stem Cells
por: Schmalz, Philip G.R., et al.
Publicado: (2011)

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
por: Jiao, Yuchen, et al.
Publicado: (2012)

Identification of Up-Regulated Genes in Malignant Glioma with Subtraction Hybridization: Preliminary Screening Studies
por: Cho, Yong Jae
Publicado: (2008)

Interrelationship between differentiation and malignancy-associated properties in glioma.
por: Frame, M. C., et al.
Publicado: (1984)

Multiple sequential molecular abnormalities in the evolution of human gliomas.
por: Venter, D. J., et al.
Publicado: (1991)

Non-Thermal Irreversible Electroporation (N-TIRE) and Adjuvant Fractionated Radiotherapeutic Multimodal Therapy for Intracranial Malignant Glioma in a Canine Patient
por: Garcia, P. A., et al.
Publicado: (2011)

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
por: Killela, Patrick J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_au804aoo710sq6e6f5n1apa3d5